Latest News

view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

  • Advances in the development of entry inhibitors for sialic-acid-targeting viruses
    Entry inhibitors might overcome the limitation of viral mutation. Antiviral research benefits from a broad-spectrum approach. Sialic acids can serve as a platform to create broad-spectrum antiviral drugs. Sialic-acid-targeting drugs such as DAS-181 are promising antiviral strategies. Multivalency is crucial when designing sialic-acid-based receptor analogues.
  • Exosomes as therapeutic solutions for pancreatic cancer
    Exosomes promote progression and metastasis in pancreatic cancer (PC). Exosomes promote chemoresistance in PC. Exosomes carry signals between PC cells and its surrounding microenvironment cells. Exosomes can be used as biomarkers or targets for PC management.
  • Therapeutic agents for targeting desmoplasia: current status and emerging trends
    Desmoplasia comprises of cellular and acellular components causing hindrance to chemotherapy. Decreased elasticity and increased interstitial fluid pressure deters drug delivery. Small molecule drugs, genes and peptide therapeutics have potential to target desmoplasia. Ongoing clinical trials on these molecules signify their potential in chemotherapy.
  • Current and future approaches to nonclinical cardiovascular safety assessment
    Developing newer modalities requires bespoke cardiovascular safety assessment. • Monitorable approaches to structural cardiotoxicity ensured clinical progression. • Link from in vitro inhibition to clinical response guided chemical design. • Disease models offer assessment of patient-relevant therapeutic index. • Focus developments in humanised models, mechanism and patient predictions.
  • Human-based evidence for the therapeutic potential of arginase inhibitors in cardiovascular diseases
    Arginase is a ubiquitous enzyme involved in nitric oxide- and polyamine-dependent vascular homeostasis. • In vitro and ex vivo human data demonstrated that overactive arginase is a key event of endothelial dysfunction, a hallmark of cardiovascular diseases. • Preliminary clinical studies confirmed that arginase inhibition is a promising therapeutic option for the treatment of cardiovascular diseases. • Only a few available arginase inhibitors are suitable for clinical use, and more research is needed.
view more

25 Hottest Articles

view more